Literature DB >> 28551648

Palliative Radiotherapy in the Local Management of Stage IVB Esophageal Cancer: Factors Affecting Swallowing and Survival.

Gen Suzuki1, Hideya Yamazaki2, Norihiro Aibe2, Koji Masui2, Kotoha Tatekawa2, Naomi Sasaki2, Takuya Kimoto2, Takeshi Nishimura2, Akihiro Nakashima2, Tadashi Takenaka2, Hitoshi Fujiwara3, Takeshi Ishikawa4, Kei Yamada2.   

Abstract

AIM: To clarify the role of external-beam radiotherapy in the local management of state IVB esophageal cancer. PATIENTS AND METHODS: We reviewed records of 31 patients with histopathologically-proven squamous cell carcinoma who underwent radiotherapy for their primary lesion. The change in dysphagia score from before to after treatment was assessed. Nutritional support-free survival (NSFS) was also evaluated.
RESULTS: The median overall survival was 6 months. The overall rate of improvement in dysphagia score was 73% (23/31). The median NSFS was 5 months. Age at presentation <67 years, tumor location in the middle thoracic esophagus, and tumor length <7 cm were associated with significant improvement in swallowing scores. Responders to radiotherapy had significantly longer NSFS than non-responders (p=0.04).
CONCLUSION: Palliative radiotherapy in the local management of stage IVB esophageal cancer is an effective treatment option for dysphagia. Factors highly associated with improvement of swallowing are age, tumor location, and tumor length. Response to radiotherapy is the most important factor in improving NSFS. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Palliation; dysphagia; esophageal cancer; radiotherapy; stage IVB

Mesh:

Year:  2017        PMID: 28551648     DOI: 10.21873/anticanres.11664

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.

Authors:  Terufumi Kawamoto; Keiji Nihei; Keisuke Sasai; Katsuyuki Karasawa
Journal:  Int J Clin Oncol       Date:  2018-07-31       Impact factor: 3.402

2.  Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases.

Authors:  Yongshun Chen; Xinyu Cheng; Haixia Song; Abraham J Wu; Geoffrey Y Ku; Percy Lee; Marije Slingerland; Kazuo Koyanagi; Shaobo Ke; Hu Qiu; Wei Shi; Yi Gao; Jiamei Chen
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  "Sandwich Therapy"-Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review.

Authors:  Lei Wu; Juan Liu; Long Liang; Mian Mao; Xiangpan Li; Tao Li; Jinyi Lang; Qifeng Wang
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  Metastatic Esophageal Carcinoma: Prognostic Factors and Survival.

Authors:  Hayam Fathy Ghazy; Hend Ahmed El-Hadaad; Hanan Ahmed Wahba; Ramy Abbas; Osama A Abbas
Journal:  J Gastrointest Cancer       Date:  2021-04-13

5.  Palliative radiotherapy and quality of life in patients with locally advanced thoracic esophageal cancer: a single centre experience from Central India.

Authors:  Kamal Bandhate; Ashok Diwan
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

6.  Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT).

Authors:  Lei Wu; Yi Wang; Baisen Li; Gang Wan; Long Liang; Tao Li; Jinyi Lang; Qifeng Wang
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

7.  Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial.

Authors:  Yun Liu; Narasimha M Beeraka; Junqi Liu; Kuo Chen; Bo Song; Zhang Song; Jianchao Luo; Yang Liu; Anping Zheng; Yanhui Cui; Yang Wang; Zhenhe Jia; Xiangyu Song; Xiaohong Wang; Hongqi Wang; Xuefeng Qi; Jinshan Ren; Liping Wu; Jixing Cai; Xainying Fang; Xin Wang; Mikhail Y Sinelnikov; Vladimir N Nikolenko; M V Greeshma; Ruitai Fan
Journal:  BMJ Open       Date:  2022-04-25       Impact factor: 3.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.